Skip to main content
Premium Trial:

Request an Annual Quote

Compugen to Collaborate with Merck Serono to Develop Peptide for Inflammatory Diseases

NEW YORK (GenomeWeb News) – Compugen will collaborate with Merck to develop a peptide that, based on recent in vitro and in vivo studies, potentially could be used in the treatment of inflammatory diseases and other indications.
The agreement covers additional research that Compugen will conduct on the CGEN-855 peptide, and gives Merck Serono an option to license it exclusively for worldwide development and commercialization.
Compugen said it discovered the peptide using its GPCR Peptide Ligands Discovery Platform. The Tel Aviv, Israel-based company also said that it currently has other peptide candidates “moving forward” in collaborations with Merck Serono, including ones that may be relevant to cancer, inflammation, metabolism, and cardiovascular disease.
Financial terms of the agreement were not released.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.